ArticleEvidence-based complementary and alternative medicine : eCAM2022
Golden Ager Chyawanprash with Meager Evidential Base from Human Clinical Trials.
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Review
- Multifunctional role of natural products for the treatment of Parkinson's disease: At a glance.Frontiers in pharmacology · 2022Review
- Emerging Role of Neuron-Glia in Neurological Disorders: At a Glance.Oxidative medicine and cellular longevity · 2022Review
- Perspectives on the Molecular Mediators of Oxidative Stress and Antioxidant Strategies in the Context of Neuroprotection and Neurolongevity: An Extensive Review.Oxidative medicine and cellular longevity · 2022Review
- The Inhibitory Effect of Polyphenon 60 from Green Tea on Melanin and Tyrosinase in Zebrafish and A375 Human Melanoma Cells.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chyawanprash (CP) is one of the most revered, effective, and best-selling health supplements of Indian Ayurvedic system of medicine, which is high on the trust and health quotient among Indian consumers. CP is an ancient synergistic blend of around fifty (50) medicinal herbs, herbal extracts with jam-like consistency, traditionally used to improve respiratory health, strengthen the immune system, prevent recurrence of infections, and over the decades is known for its anti-inflammatory and antioxidant properties. With the recent growth of commercialization, this traditional preparation is gaining popularity across the world. Various pharma firms are engaged in its commercial production, and this recipe is easily available on market shelves, with a common brand name "Chyawanprash." The consumers generally pop up with some genuine queries or doubts regarding its usage and benefits. Though CP is well-trusted traditional preparation, however, limited scientific literature is available on understanding its clinical role. This critical review discusses the general consumer queries apropos its usage, critically analyzing the reported clinical studies, perspectives, and unmapped areas for future research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.